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Background: HIV-1 gene expression is driven by the long terminal repeat (LTR), which contains many binding sites
shown to interact with an array of host and viral factors. Selective pressures within the host as well as the low
fidelity of reverse transcriptase lead to changes in the relative prevalence of genetic variants within the HIV-1
genome, including the LTR, resulting in viral quasispecies that can be differentially regulated and can potentially
establish niches within specific cell types and tissues.
Methods: Utilizing flow cytometry and electromobility shift assays, specific single-nucleotide sequence polymorphisms
(SNPs) were shown to alter both the phenotype of LTR-driven transcription and reactivation. Additional studies also
demonstrated differential loading of transcription factors to probes derived from the double-variant LTR as compared
to probes from the wild type.
Results: This study has identified specific SNPs within CCAAT/enhancer binding protein (C/EBP) site I and Sp site
III (3 T, C-to-T change at position 3, and 5 T, C-to-T change at position 5 of the binding site, respectively) that alter
LTR-driven gene transcription and may alter the course of viral latency and reactivation. The HIV-1 LAI LTRs
containing the SNPs of interest were coupled to a plasmid encoding green fluorescent protein (GFP), and polyclonal
HIV-1 LTR-GFP stable cell lines utilizing bone marrow progenitor, T, and monocytic cell lines were constructed and
utilized to explore the LTR phenotype associated with these genotypic changes.
Conclusions: Although the 3 T and 5 T SNPs have been shown to be low-affinity binding sites, the fact that
they can still result in effective HIV-1 LTR-driven gene expression, particularly within the TF-1 cell line, has suggested that
the low binding site affinities associated with the 3 T C/EBP site I and 5 T Sp site III are potentially compensated for
by the interaction of nuclear factor-κB with its corresponding binding sites under selected physiological and cellular
conditions. Additionally, tumor necrosis factor-α and Tat can enhance basal transcription of each SNP-specific
HIV-1 LTR; however, differential regulation of the LTR is both SNP- and cell type-specific.
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HIV-1-associated immunologic and neurologic disease is
dependent on the ability of the virus to infect subsets of
resident immune and central nervous system (CNS) cell
populations. In vitro and in vivo investigations have
shown that HIV-1 infection of active CD4+ T lymphocytes
initiates a highly productive infection [1-7]. In contrast,
HIV-1-infected monocytic cell populations produce only
limited quantities of virus due to several host-cell replica-
tion blocks including barriers that limit the reverse tran-
scription process [8,9] and nuclear import [10]. These
barriers result in a more chronic infection because this cell
type is more resistant to the cytopathic effects of HIV-1
gene products [11-13] and has a longer lifespan in vivo.
The chronic nature of HIV-1 replication in cells of the
monocyte-macrophage lineage is likely a contributor to
the central importance of these cells in evasion of HIV-1
detection and elimination by the immune system and the
maintenance of viral reservoirs. The virus can utilize cells
of this lineage as a vehicle facilitating its transport across
the blood–brain barrier (BBB) and its entry into the CNS
[14-16], thereby promoting HIV-1-associated neuropatho-
genesis and the development of minor neurocognitive
impairment, as well as the more severe CNS disease, HIV-
1-associated dementia (HIVD). HIV-1 infection of the
CNS occurs soon after infection; however, under most cir-
cumstances, prolonged productive viral replication, char-
acterized by the formation of multinucleated giant cells
with progressive loss of cognitive, behavioral, and motor
deficits, is likely to occur only after severe immunosup-
pression and breakdown of the BBB. The pathological
events that eventually lead to the development of HIVD
may be initiated outside the CNS and involve the process
of monocyte activation and many important events associ-
ated with passage of activated cells across the BBB. Peri-
vascular macrophages likely play a critical role in the
pathogenesis of HIVD as they are located on the paren-
chymal side of the BBB and the pool is continuously
renewed through bone marrow-derived macrophages, par-
ticularly during CNS inflammation [14]. Thus, the bone
marrow may serve as a source of HIV-1-infected macro-
phages and may play a critical role in neuroinvasion and
progression of CNS disease.
Genetic variation within the HIV-1 viral genome is a
naturally occurring process driven by the low fidelity of
reverse transcriptase, coupled with the selective pressures
brought about within the host such as antiretroviral ther-
apy, recreational drug use, immunological pressures, viral
recombinatory events, host-cell phenotype, and rates of
virus production [17-19]. These events result in single nu-
cleotide polymorphisms (SNPs) throughout the genome
including the promoter region, designated the long ter-
minal repeat (LTR). Genetic variation occurs within LTR
binding sites where host transcription factors and viralregulatory proteins bind, altering the way the LTR drives
viral transcription. The resultant viral quasispecies are
likely shaped by the selective pressures operative within a
variety of cellular and tissue niches that ultimately
maintain specific sets of quasispecies to form viral reser-
voirs in susceptible cell types and end-organ tissues
[20-27]. The accumulation of specific LTR sequence
configurations over time may also result from accumu-
lation of poorly replicating viruses or latent proviruses
in long-lived cell subsets in circulation or within viral
reservoirs, such as the resting memory CD4+ T-cells,
monocytes and macrophages, and hematopoietic pro-
genitor cells (HPCs) [28].
Transcription factor binding sites within the LTR alter-
natively recruit both activating and repressing factors
that can phenotypically alter the basal and inducible rates
of viral gene expression [29-33]. This differential regula-
tion may ultimately impact viral replication in both a cell
type- and a tissue-specific manner [13,21,34,35] that may
impact the course of HIV-1 disease [36]. Due to sequence
variation within the LTR, cis-acting transcription factor
binding sites in the LTR may be functionally altered
during the evolution of quasispecies, resulting in altered
promoter activity [20-22] and altered transcription factor
binding [23,25-27]. Studies in the pre-HAART era have
demonstrated that specific HIV-1 LTR CCAAT/enhancer
binding protein (C/EBP) and Sp protein binding site
configurations that arise as a consequence of quasispe-
cies evolution, such as a C-to-T SNP at nucleotide pos-
ition 3 in C/EBP site I within the context of a subtype B
consensus sequence binding site (designated 3 T) and
the C-to-T change at nucleotide position 5 in Sp binding
site III (designated 5 T), were preferentially encountered
in patients with more severe disease [23,37] and the
brains of patients with HIVD [37]. Specific nucleotide
changes within the LTR, such as the 3 T and 5 T, abro-
gate binding of cognate transcription factors to their
corresponding binding site [23,25-27,37,38]. Variations
in the Sp GC box array of the viral promoter result in
altered rates of viral gene expression and viral replica-
tion [39-44]. In addition, in the HAART era the 5 T
SNP in Sp site III has been found to occur almost as fre-
quently as the consensus B (conB; derived January 2002
by the Los Alamos National Laboratory) for that site
within the DREXELMED HIV/AIDS Genetic Analysis
Cohort, which currently consists of approximately 500
HIV-1-infected patients (data not shown). Furthermore,
in a small subset of those patients, the 3 T and 5 T SNPs
occur together. Therefore, to better understand the sig-
nificance of specific SNPs found in current and past
HIV/AIDS cohorts with respect to promoter function,
LTR activity was examined in the TF-1 progenitor, U-937
monocytic, and the Jurkat T-cell lines within a chromatin-
based environment.
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Parental (wild-type) and 3T5T LTR results in cell
type–specific phenotypes within different promoter
backbones
The DREXELMED HIV/AIDS Genetic Analysis Cohort
is currently comprised of approximately 504 patients,
78.26% of whom are on continuous highly active anti-
retroviral therapy (HAART). Within this patient cohort,
457 patients and 1,113 longitudinal samples have been
genotyped and the HIV-1 LTRs contain many SNPs, in-
cluding the previously identified C-to-T SNP at position
5 (5 T) in Sp site III, that occurs in approximately 24.9%
of the LTRs analyzed to date compared to the conB se-
quence (GAGGCGTGGC) derived from the Los Alamos
National Laboratory, which occurs at in about 67.8% of
the LTRs analyzed. The 5 T SNP results in dramatically
reduced binding of Sp1, Sp3, and the truncated form of
Sp3 [23]. Approximately 5.1% of the patients within this
cohort have a SNP within the LTR at C/EBP site I
(AGCTTTCTACAA), where there is a C-to-T change at
position 3 (3 T) that also results in a knockout binding
phenotype [23,25-27,37,38]. Finally, a small number of























Figure 1 Parental (wild-type; WT) and 3T5T long terminal repeat (LTR
promoter backbones. TF-1, U-937, and Jurkat cells were stably transfected
fluorescent protein expression vector (pEGFP-N1) using the AMAXA Nucleo
introduce the position 3 C-to-T change at CCAAT/enhancer binding protein
cytometric analysis was used to measure the ability of the variant LTR to d
The fluorescence patterns in untransfected cells are depicted in gray. The LGenetic Analysis Cohort have been found to have the
3T5T double variant.
As one approach to understand the effects of the 3 T
and 5 T variations together on LTR-driven gene expres-
sion within several backbones, the WT and 3T5T varia-
tions were introduced into the LAI, YU-2, and 89.6 HIV-1
LTR backbones and then ligated into the pEGFP-N1 vec-
tor where the LTR can drive the expression of the green
fluorescent protein (GFP). The constructs were then sta-
bly transfected into TF-1, U-937, and Jurkat cells. These
cells were selected because they were all representative of
cellular phenotypes that have been identified as potential
or confirmed viral reservoirs where HIV-1 could poten-
tially avoid recognition from immune cells and thera-
peutic agents, thus enabling the virus to survive for long
periods within the host and to continue to replicate
when the intra- and extracellular environment was con-
ducive to virus production [2,13,28,33,45]. Within TF-1
cells, the 3T5T YU-2 and 89.6 LTRs resulted in both a
nonexpressing population and a high-expressing popu-
lation (Figure 1), whereas the 3T5T LAI LTR also re-
sulted in an intermediate-expressing population. The
intermediate-expressing population of cells was alsoU-2 89.6 
transfected 3T5T LTR WT LTR 
) results in cell type–specific phenotypes within different
with the HIV-1 LAI, YU-2, and 89.6 LTRs, which were placed in a green
fector System (Lonza, Basel, Switzerland). Mutagenesis was used to
(C/EBP) site I and a position 5 C-to-T change at Sp site III (3T5T). Flow
rive GFP expression as compared with their parental (WT) counterparts.
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Figure 2 Cell populations independently recovered from
low-temperature storage resulted in two general phenotypes
with respect to HIV-1 3T5T long terminal repeat–green
fluorescent protein (LTR-GFP) basal expression. TF-1, U-937, and
Jurkat cells were stably transfected with the HIV-1 LAI LTR, which
was placed in a GFP expression vector (pEGFP-N1) using the AMAXA
Nucleofector System (Lonza, Basel, Switzerland). Mutagenesis was
used to introduce the position 3 C-to-T change at CCAAT/enhancer
binding protein (C/EBP) site I (3 T), a position 5 C-to-T change at Sp
site III (5 T), or to introduce both the 3 T and 5 T variants into the
same LAI LTR (3T5T). Flow cytometric analysis was used to measure
the ability of each LTR to drive GFP expression as compared with their
parental (WT) counterparts. The fluorescence patterns in untransfected
cells are depicted in gray. The LAI WT LTR is shown in red; LAI 3 T LTR
in green; LAI 5 T LTR in orange; and the HIV-1 LAI 3T5T LTR in blue.
Phenotype expression pattern 1 is shown by panels on the left, while
the phenotype expression pattern 2 is shown by panels one the right.
All cells were analyzed by flow cytometry for basal levels of LTR-driven
GFP expression between passages 6 and 8.
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LTR, whereas it was absent from U-937 cells containing
the 3T5T YU-2 or 89.6 LTRs (Figure 1). In contrast, no
phenotypic differences were found between the WT and
3T5T LAI, YU-2, or 89.6 LTRs within Jurkat cells
(Figure 1), indicating that this cell phenotype may play
in differentially controlling expression of LTRs containing
genotypic alterations. The LAI backbone was selected for
further study due to the presence of the large intermediate
expressing cell population within cells containing the
3T5T LAI backbone that was mainly absent in both the
YU-2 and 89.6 backbones (Figure 1). Additionally, it has
been commonly used in other scientific studies, shares se-
quence similarity with the conB sequence except that it
contains a 6G change within C/EBP site I, and the HIV-1
LAI virus has the ability to infect all three cell line models
used in this study.
Double-variant LTR results in two different phenotypes in
hematopoietic progenitor, promonocytic, and Jurkat T cells
Transfected cells were selected under G418 selective
pressure for over 4 weeks to develop stably transfected
cell lines. Those cell lines were then frozen and preserved
for future experimental use. As one approach to under-
standing the basic effects of genetic variation on LTR
function, basal LTR-driven GFP expression was assessed
using flow cytometry to examine the LTR-driven GFP
expression patterns obtained from a number of cell pop-
ulations independently recovered from low-temperature
storage.
Interestingly, each recovered cell population resulted
in different LTR-driven expression patterns. This was
particularly evident within the cell populations containing
the 3T5T double-variant LTR, which could be grouped
into two general phenotypic expression patterns. Stored
frozen cells were independently recovered and grown in
culture conditions more than six times each; representa-
tive histograms are shown in Figure 2. With TF-1 cells,
generally phenotype 1 was characterized by a very small
nonexpressing population of cells, in addition to a larger
population of cells that express intermediate levels of
LTR-driven GFP expression (Figure 2, top left). Within
TF-1 cells, phenotype 2 was generally characterized by a
large population of non-GFP-expressing cells as well as
a population of cells that expressed both intermediate
and high levels of GFP (Figure 2, top right). The TF-1
cell lines containing the HIV-1 parental LAI LTR as well
as the 3 T and 5 T variant LTR generally exhibited the
same two LTR-driven GFP expression phenotypes in
that they exhibited large non-GFP-expressing popula-
tions of cells and a smaller high-GFP-expressing popu-
lation of cells (Figure 2, top panels). The 5 T genotype
generally resulted in higher amounts of LTR-driven GFP
expression (Figure 2, top panels) when compared withGFP expression driven by the WT and 3 T-containing
LAI LTR.
Similar to the stably transfected TF-1 cells, basal LTR-
driven GFP expression from stably transfected U-937
cell populations independently recovered from low-
temperature storage also resulted in two distinct pheno-
types specifically visible with the 3T5T-containing LTR
cell populations (Figure 2, middle panels). In the U-937
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expressing population with a larger intermediate-GFP-
expressing population (Figure 2, middle left), whereas
the 3T5T U-937 phenotype 2 cell population included a
large non-GFP-expressing cell population and large popu-
lations of intermediate- and high-GFP-expressing cells
(Figure 2, middle right). With respect to the U-937 cell
populations carrying other LTR genotypes (WT, 3 T, and
5 T), the expression profiles consisted of mainly non/low
levels of GFP expression and smaller populations of
intermediate-GFP-expressing cells (Figure 2, middle panel).
When the stably transfected Jurkat cells were recovered
from low-temperature storage, they too displayed two dis-
tinct phenotypes. Phenotype 1 was characterized by a large
low-expressing population of GFP-expressing cells within
all Jurkat cell populations carrying each genotype and
smaller populations of intermediate/high-GFP-expressing
cells (Figure 1, bottom left). Within phenotype 2, there was
a large population of nonexpressing cells that was similar
to the WT Jurkat cell population, and a smaller population
of cells that exhibited low/intermediate levels of GFP ex-
pression (Figure 2, bottom right).
Double-variant LTR results in altered gene expression in
basal and stimulated stably transfected cell lines
To better understand the kinetics behind LTR-driven
gene transcription within LTRs that contained the SNPs
of interest, the genotypic changes were analyzed in the
presence of LTR activators such as tumor necrosis factor
(TNF)-α and the viral transactivating protein Tat. For
the following studies, TF-1, U-937, and Jurkat cell popu-
lations displaying phenotype 2 were selected for further
study because of their large populations of non-GFP-
expressing cells, which could represent a model cell line
population representative of known cellular HIV-1 reser-
voirs within the body containing an integrated LTR struc-
ture in a non-expressing or silent mode that could be
activated under the selected physiological conditions.
Inflammatory cytokines such as TNF-α are elevated in
patients with AIDS, and these particular cytokines are
also involved in monocyte-macrophage differentiation as
well as activation of HIV-1 gene transcription [46-53].
To study the effects of inflammatory cytokines on genet-
ically altered LTR-driven gene expression in TF-1, U-
937, and Jurkat cells, cells were treated with TNF-α (20
ng/mL) for 24 hours, after which time GFP expression
was analyzed using flow cytometry. TNF-α stimulated
cells of the monocytic and T-cell lineage through the
binding of TNF-α to the TNF receptor, which causes the
phosphorylation and release of IκB from nuclear factor-
κB (NF-κB), in turn allowing NF-κB to translocate from
the cytoplasm into the nucleus of the cell. NF-κB has
then been shown to be able to activate many host and
viral genes through the initial recruitment of the positivetranscription elongation factor, as previously reviewed
[45]. In addition, in the absence of functional Sp sites, NF-
κB binding to the enhancer region of the LTR can result
in alteration in viral replication in T cells [43-45,54]. As
expected, the cells were stimulated by exposure to TNF-α,
and as a result of the stimulation, LTR-driven gene ex-
pression was increased in each of the cell populations
containing the selected LTR genotypes (Figure 3, middle
row). In cells expressing the WT, 3 T, and 5 T LTRs,
there was still a large population of cells that remained
nonexpressers, while there was also a shift in the low-
intermediate-expressing cells to a higher level of GFP
expression (Figure 3). Interestingly, the 5 T LTR resulted
in a higher level of change in LTR-driven GFP expression
than the WT LTR, indicating that this genotype (which
occurs frequently in the DREXELMED HIV/AIDS Genetic
Analysis Cohort) could be involved in evading immune
activation within the host under basal conditions, but
under stimulatory conditions the 5 T genotype could be
activated to produce a higher level of gene expression and
virus production. Additionally, the stimulated 3T5T LTR
exhibited a shift of the low-intermediate-GFP-expressing
cell population to a majority of cells expressing a high
level of GFP, and the majority of the nonexpressing cell
population shifted to an intermediate level of GFP expres-
sion (Figure 3).
Unexpectedly, the U-937 cells expressing GFP driven
by the WT, 3 T, and 5 T LTRs were not stimulated to
any great extent by TNF-α treatment. Normally, TNF-α
would cause U-937 cells to differentiate from their promo-
nocytic state into monocyte-macrophages, which would
lead to an alteration in general cellular gene expression
(Figure 3). In contrast, as a result of the stimulation, the
3T5T LTR-driven gene transcription and gene expression
as modeled by GFP expression were elevated (Figure 3). In
these cells, the population of nonexpressing cells showed
no change in GFP expression; however, the lower-GFP-
expressing cell population decreased in prevalence dra-
matically, resulting in a separate population of cells
expressing intermediate/high levels of GFP as driven by
the 3T5T LTR.
During infection with HIV-1, the virus primarily in-
fects and replicates in activated CD4+ T cells. Despite
the short lifespan of infected CD4+ T cells, a small frac-
tion of infected, activated T cells return back to a resting
memory state in which the virus no longer replicates.
This phenomenon results in a stable, persistent viral in-
fection that is transcriptionally silent until the cell is
reactivated. The memory CD4+ T-cell has been the most
widely studied latently infected cell phenotype, and these
studies have provided extensive knowledge concerning
how HIV-1 may remain latent in a cellular viral reser-
voir. The Jurkat T-cell line is comprised of quiescent,
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Figure 3 Double-variant 3T5T long terminal repeat (LTR) results in altered gene expression in the stably transfected cell lines. U-937
cells were stably transfected with the LAI LTR, cloned within the context of the green fluorescent protein expression vector pEGFP-N1 using
the AMAXA Nucleofector System (Lonza, Basel, Switzerland). Mutagenesis was performed to introduce the position 3 C-to-T change at CCAAT/
enhancer binding protein (C/EBP) site I (3 T), a position 5 C-to-T change at Sp site III (5 T), or to introduce both the 3 T and 5 T mutations into a
single LTR (3T5T). Flow cytometric analysis was used to measure the ability of each LTR to drive GFP expression as compared with their parental
(WT) counterparts. Untransfected cells are depicted in gray. The LAI WT LTR is shown in red; LAI 3 T LTR in green; LAI 5 T LTR in orange, and the
LAI 3T5T LTR in blue. Under basal conditions, cells expressing the 3T5T LTR expressed an intermediate level of GFP when compared with WT and
the other variants that mainly had low GFP expression. Stably transfected cells were treated with TNF-α (20 ng/mL) for 24 hours and then GFP
expression was assessed using flow cytometry. The cells expressing the 3T5T LTR resulted in an increase in the high-GFP-expressing population. In
addition, cells expressing GFP driven by the 3 T LTR showed a great increase in high-GFP-expressing cells. Stably transfected cells were transfected
with Tat86 (300 ng) using the AMAXA Nucleofector System. Tat stimulation of the LTRs was shown to drive a very high level of GFP expression in
the 3T5T LTR-GFP-expressing cells, and a small increase in intermediate/high-GFP-expressing cells when driven by the 3 T LTR.
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HIV-1-infected patient. To study the activity of the 3 T,
5 T, and 3T5T LTRs within the Jurkat cell line, stably
transfected cells stimulated with TNF-α (20 ng/mL), and
as a result the WT, 3 T, 5 T, and 3T5T LTRs displayed
an increase in LTR-driven gene transcription (Figure 3).
The LAI 3 T and 5 T LTRs exhibited a slightly higher
level of gene transcription when stimulated, indicating
that there might be a cell type-specific LTR activation
with a specific genotype.
Double-variant LTR results in more efficient binding of
NF-κB complexes to the LTR
As seen in Figures 2 and 3, the 5 T and 3T5T SNPs re-
sulted in altered LTR-driven GFP expression. To deter-
mine whether the 5 T and 3T5T SNPs altered binding of
transcription factors to their cognate binding sites on
the LTR, and whether the 3T5T SNP could potentially
lead to altered and more efficient binding of NF-κBcomplexes to NF-κB site I and site II, electromobility
shift assays were performed. Nuclear extract was isolated
from WT untransfected TF-1 cells that were untreated
or treated with 20 ng/mL TNF-α for 24 hours and then
incubated with the long probes containing the WT, 3 T,
5 T, and 3T5T variants depicted in Figure 4A. Extracts
were also incubated in the absence or presence of gel
shift antibodies against NF-κB p50 and p65. When ex-
tracts were incubated with the 5 T and 3T5T long probe,
in both activated and nonactivated conditions, a large
molecular weight complex (arrow 1 in Figure 4B) formed
more prominently with those two probes in comparison
to the others. Additionally, incubation with the NF-κB
p50 antibody resulted in abrogation of binding of that
complex to the long probe, and a shift in activated extracts
incubated with the 5 T and 3T5T probes (arrow 2 in
Figure 4B). This observation indicates that 5 T and 3T5T
configurations allow for better binding of NF-κB p50 to its
cognate binding site, potentially due to the lack of steric
Figure 4 Nuclear factor-κB (NF-κB) p50 and p65 bind more efficiently to the 5 T and 3T5T long terminal repeats (LTRs). Nuclear extract
was isolated from normal and tumor necrosis factor-α (TNF-α)-treated TF-1 cells. (A) An LAI long probe covering CCAAT/enhancer binding protein
(C/EBP) site I, NF-κB site II, NF-κB site I, and Sp site III with the wild-type (WT), 3 T, 5 T, or 3T5T single-nucleotide polymorphisms (SNPs) was
used to determine differences in complex formation at each LTR. TF-1 nuclear extract was incubated with probe in the absence or presence of
(B) NF-κB p50 or (C) p65 gel shift antibodies for 30 minutes. (B) Normal and activated extracts incubated with the 5 T and 3T5T long probe
showed greater complex formation and abrogation and shift of complex formation when incubated with NF-κB p50 antibody (black arrows).
(C) Normal and activated extracts incubated with the 5 T and 3T5T long probe showed greater complex formation and abrogation of complex
formation when incubated with NF-κB p65 antibody (black arrow).
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tracts were incubated with long probes and the NF-κB
p65 antibody, again, the same high molecular weight com-
plex was more abundant with the 5 T and 3T5T probes,
and binding of that complex to all probes was abrogatedwith the NF-κB p65 antibody (arrow in Figure 4C). The
inability of C/EBP and Sp factors to bind efficiently to the
mutated binding sites probably leads to the more efficient
binding of NF-κB factors. These results also indicate that
under activated conditions, that there is a larger complex
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it is comprised of NF-κB p50 and p65, suggesting that
under normal conditions, the loading is not as effective.
This could explain the intermediate levels of expression
observed in Figure 3, and under activated conditions the
much higher level of activation that occurs with those
genotypes.
Stably transfected cell clones from TF-1 and U-937 cell
lines reflect the GFP expression profiles of the total
populations used to select the cell clones
In order to effectively study how the LTR functions to
drive GFP expression from the standpoint of a single cell,
sets of clones were developed from each stably transfected
cell line (TF-1 and U-937) using serial dilution and then
propagating a population from a single cell. Once each
single cell gave rise to a population of clones, their basal
level of LTR-driven GFP expression was assessed by flow
cytometry. Each clonal population was designated into
one of three categories: nonexpresser, intermediate ex-
presser, or high expresser based on arbitrary designations
from the geometric mean fluorescence intensity (MFI)
and GFP-positive cell percentage (Figure 5A). Figure 5B
displays representative histograms for stably transfected
TF-1 clonal populations containing the WT, 3 T, 5 T, or
3T5T LTR that fall into each category. There are a total of
four nonexpresser and one high-expresser TF-1 LAI LTR
WT clones; three nonexpressing and three intermediate-
expressing TF-1 LAI LTR 3 T clones; two nonexpressing
and two high-expressing TF-1 LAI LTR 5 T clones; and
three nonexpressing and two intermediate-expressing TF-
1 LAI LTR 3T5T clones (Figure 5B). When these clones
were compared with the populations from which they
were derived (Figure 3, top panel), their expression pro-
files are representative of the variant cell line from the ex-
pression pattern observed under basal conditions prior to
cell cloning. Figure 5C displays representative histograms
for stably transfected U-937 promonocytic clonal popula-
tions containing the WT, 3 T, 5 T, or 3T5T LTR that fall
into each category. There are a total of 10 nonexpressing
and one intermediate-expressing U-937 LAI LTR WT
clones; three nonexpressing, one intermediate expressing,
and two high-expressing U-937 LAI LTR 3 T clones; two
nonexpressing and two intermediate-expressing U-937
LAI LTR 5 T clones; and three intermediate-expressing
U-937 LAI LTR 3T5T clones (Figure 5C). Interestingly,
the Jurkat T-cell clones were difficult to propagate be-
cause as single cells, they would become quiescent and
had a propensity to die quickly instead of multiplying.
Therefore it was difficult to obtain a large number of
Jurkat T-cell clones to study. Additionally, because of
the low LTR-driven GFP activation within the Jurkat T-
cell populations, they were no longer used for the pur-
poses of this study.Nonexpressing 3T5T LAI LTR within TF-1 cells can be
induced to drive GFP expression
Because of the expression phenotypes observed with the
nonexpressers and intermediate expressers, it was of inter-
est to determine whether stimulation of the LTR with in-
flammatory cytokines could induce these LTRs to drive
GFP expression. If so, this might represent a model for
“promoter latency and reactivation” within the bone mar-
row progenitor cell type with LTRs containing naturally
occurring SNPs. TF-1 cell clones were treated with TNF-α
(at 20, 50, 100, 200, or 300 ng/mL) to determine whether
inflammatory cytokine induction of the LTR could drive
GFP expression in these cells. Clones that had higher
levels of GFP expression were used as controls to show
that the LTR was inducible through treatment. The titra-
tion of TNF-α concentrations resulted in very similar
levels of LTR-induced GFP expression (data not shown).
Therefore, in this and subsequent experiments, only repre-
sentative data showing the results of the TNF-α treatment at
20-ng/mL were shown (Figure 6). Under stimulated condi-
tions, the high-expressing TF-1 clones containing the LAI
WT or 5 T LTR drove a higher level of GFP expression than
the same unstimulated LTRs (Figure 6). In contrast, under
the same conditions, the TF-1 nonexpressing clones contain-
ing the LAI WT or 5 T LTRs were not stimulated to drive
GFP expression. Stimulated nonexpressing TF-1 clones con-
taining the LAI 3 T LTR were not induced into driving
higher levels of GFP expression; however, the intermediate-
expressing clone used as a control was induced and was
thereby able to drive a higher level of GFP expression. Inter-
estingly, the difference in MFI values between stimulated and
unstimulated GFP levels of expression was greater with the
clone containing the 3 T variant than the difference between
stimulated and unstimulated MFI observed with the WTand
5 T LTRs. As shown in Figure 5B, the 3T5T LAI LTR re-
sulted in both a population and clones that had intermediate
levels of LTR-driven GFP expression. Therefore, for this
experiment, a low-expressing clone and an intermediate-
expressing clone were selected to represent non- and high-
expressing clones, respectively. Under stimulated conditions,
the low- and intermediate-expressing LTRs drove a higher
level of GFP expression than in unstimulated conditions
within the TF-1 cell background. However, the low-
expressing 3T5T cell clone had a larger difference in MFI
between unstimulated and stimulated conditions when com-
pared with the intermediate-expressing cell clone (Figure 6).
U-937 clones containing nonexpressing LTR phenotypes
cannot be induced into driving GFP expression
To determine whether the non/low-GFP-expressing phe-
notypes observed within the U-937 cell clones could be
induced into expression, unlike the stably transfected
TF-1 cell clones, each of the cell clones was treated with
TNF-α (20 ng/mL) for 24 hours and then analyzed for
Name Non/low-expresser Intermediate-expresser High-expresser Total
LAI WT 4 0 1 5
LAI 3T 3 3 0 6
LAI 5T 2 0 2 4
LAI 3T5T 3 2 0 5
100 
High-expresser 
Name Non/low-expresser Intermediate-expresser High-expresser Total
LAI WT 10 1 0 11
LAI 3T 3 1 2 6
LAI 5T 2 2 0 4










































 A.  Determination of expression level groups for cell clones   
 B.  Expression groups of TF-1 cell clones   
 C.  Expression groups of U-937 cell clones   
Name Non/low-expressers Intermediate-expressers High-expressers
MFI range 0-15 16-50 >50
% positive cells range 0%-10% 11%-70% 71%-100%
0 
97.5 80.7 19.3 0.9 99.1 
98.9 45.5 12.6 
Figure 5 Cell clones developed from total populations of stably transfected TF-1 and U-937 cell lines reflect the green fluorescent
protein (GFP) expression profile of the parental populations. The TF-1 and U-937 cells that were stably transfected with the LAI long terminal
repeats (LTR) (wild-type [WT], 3 T, 5 T, and 3T5T) were serially diluted in order to obtain 1 cell in 1 mL of media (approximately 1 cell in 10 wells
of a 96-well plate). Cell clone populations were propagated from a single cell and then were analyzed using flow cytometry for their basal GFP
expression. The clonal populations were then designated in one of three categories (nonexpresser, intermediate expresser, and high expresser)
based on their geometric mean fluorescence intensity (MFI) and their percent cell positive values (A). Representative histograms showing levels
of GFP expression by the stably transfected cell clone (black line) compared with the untransfected control cell line (gray line) for TF-1 (B), U-937
(C), cell clones expressing the LAI WT, 3 T, 5 T, or 3T5T LTRs. The histograms show that the TF-1 and U-937 cell clones mimic their parental
population counterparts in terms of basal GFP expression profiles. Tables below each set of histograms show the total number of clonal cell
populations for each LTR genotype that falls within one of the three expression phenotypes.
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representative histograms from both nonexpressing and
expressing phenotypes within each backbone expressed
within the stably transfected U-937 cell clones. With TNF-
α stimulation, the high-expressing cell clone containing theLAI 3 T LTR drove a higher level of GFP expression than
the same unstimulated LTR (Figure 7). In contrast, under
the same conditions, the nonexpressing clone containing
the LAI 3 T LTR was not stimulated to drive GFP ex-





























LAI 3T5T LAI 3T5T 
Figure 6 Nonexpressing TF-1 cell clones containing the 3T5T
LAI long terminal repeat (LTR) could be induced into
LTR-driven green fluorescent protein (GFP) expression. TF-1 cells
stably transfected with the HIV-1 LAI LTR (wild type [WT], 3 T, 5 T,
and 3T5T) were serially diluted in order to obtain 1 cell in 1 mL of
media (approximately 1 cell in 10 wells of a 96-well plate). Cell clone
populations were propagated from the single cell and then were
analyzed using flow cytometry for their basal GFP expression. The
clonal populations were then designated in one of three categories
(nonexpresser, intermediate expresser, and high expresser) based
on their geometric mean fluorescence intensity (MFI) and their
percent cell positive values (Figure 5A). Non/low-expressing and
high-expressing LAI WT and LAI 5 T LTR containing clones were
treated with a range of tumor necrosis factor-α (TNF-α) concentrations
(20–300 ng/mL). Representative histograms (at a TNF-α concentration
of 20 ng/mL) showing levels of GFP expression obtained with the
untreated, stably transfected cell clone (solid turquoise line) compared
with the treated, stably transfected cell clone (dashed turquoise line),
untreated WT TF-1 cells (solid black line), and treated WT TF-1 cells































Figure 7 U-937 cell clones containing nonexpressing wild-type
(WT) and variant long terminal repeats (LTRs) cannot be
induced into driving green fluorescent protein (GFP) expression.
U-937 cells stably transfected with the LAI LTR (WT, 3 T, 5 T, and
3T5T) were serially diluted in order to obtain 1 cell in 1 mL of media
(approximately 1 cell in 10 wells of a 96-well plate). Cell clone
populations were propagated from the single cell and then were
analyzed using flow cytometry for their basal GFP expression. The
clonal populations were then designated in one of three categories
(nonexpresser, intermediate expresser, and high expresser) based on
their geometric mean fluorescence intensity (MFI) and their percent
cell positive values (Figure 5A). Nonexpressing and expressing cell
clones were treated with a range of tumor necrosis factor-α (TNF-α)
concentrations (20–300 ng/mL). Representative histograms (at a
TNF-α concentration of 20 ng/mL) showing levels of GFP expression
obtained with the untreated, stably transfected cell clone (solid
turquoise line) compared with the treated, stably transfected cell
clone (dashed turquoise line), untreated WT U-937 cells (solid black
line), and treated WT U-937 cells (dashed black line). As there were
no nonexpressing U-937 3T5T LTRs containing clones, they are
excluded from the non/low-expressing cell clone column. Each
clone shown is a representative of the group.
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driving higher levels of GFP expression; however, the
intermediate-expressing clones that were used as con-
trols for each backbone were able to be induced and
drive higher levels of GFP expression. Interestingly, the
low-intermediate-expressing phenotype within the U-937
LAI WT cell clone had the largest difference in unstimu-
lated versus stimulated MFIs (33.4 and 80.7, respectively)
and percent positive GFP-expressing cell number (9.67%
and 98.5%, respectively). As shown in Figure 5C and as
one might expect, the 3T5T LAI LTR resulted in clones that
had varying intermediate levels of LTR-driven GFP expres-
sion. Therefore, for this experiment, only one intermediate-
expressing clone was selected to represent a high-expressing
phenotype (Figure 7, bottom panels). Under stimulated con-
ditions, the intermediate clone exhibited a transition into
high-GFP-expressing cells, in comparison to the stimulated
levels of the expressing clones containing the WT, 3 T, or
5 T LTRs.
Discussion
Genetic variation within the HIV-1 genome is a naturally
occurring phenomenon because of the low fidelity of re-
verse transcriptase as well as selective pressures present
within the host [17,18]. These viral quasispecies are po-
tentially able to establish niches and reservoirs within
HPCs, cells of the monocyte-macrophage lineage, as well as
T cells that can reseed infection into the periphery and
CNS of infected patients and possibly other end organs as
well [20-28]. Nucleotide changes within the NF-κB-
proximal C/EBP and Sp transcription factor binding sites
within the viral promoter have been observed in both the
pre-HAART and HAART eras and have been shown to
guide differential regulation of viral expression by the LTR
[20-22,55-57]. Interestingly, the prevalence of the 3 T, 5 T,
and 3T5T LTR variants in the HAART era, at least in the
DREXELMED HIV/AIDS Genetic Analysis Cohort is lower
when compared to the levels observed from published
studies in the pre-HARRT era [23-27,37]. However, the
DREXELMED HIV/AIDS Genetic Analysis Cohort is over-
all much healthier because of the prolonged use of combin-
ation antiretroviral therapy. However, we hypothesize that
the prevalence of the 3 T, 5 T, and 3T5T LTR variants will
become more prevalent with the development of greater
disease severity across this HIV-1-infected patient popula-
tion. In fact, one of the patients that has shown severe CD4
decline and neurologic impairment carries both of these
variations as we have previously published [19].
The TF-1, U-937, and Jurkat T-cell lines were used as
models of HPCs, monocytes, and CD4+ T cells, respect-
ively, in order to study the effects of the previously de-
scribed SNPs on LTR-driven gene expression within a
chromatin-based microenvironment. Each cell type was
stably transfected with a specific LTR variant of interestand then stored at low temperature for prolonged pe-
riods prior to experimentation. Flow cytometric analysis
showed that subsequent recovery of the stored cell pop-
ulations containing the HIV-1 variant LTR resulted in
two different LTR-driven GFP expression phenotypes
with each model cell line (TF-1, U-937, and Jurkat) and
parental or variant LTR (3 T, 5 T, and 3T5T) (Figure 2).
We theorized that once multiple cell samples were stored
at low temperature for prolonged periods, the same ex-
pression phenotype would be maintained for each sample
that was recovered from storage and passaged to approxi-
mately the same level. However, as shown in Figure 2, this
was not the case; several phenotypes were associated with
the specific genotypic changes within the LTRs stably
transfected across all model cell lines. Alterations in gene
expression from cells recovered from low-temperature
storage could be caused by differences in the stably trans-
fected cells that survive the thaw and reculturing process.
Cell death is a major problem when the cell line popula-
tions are thawed and recultured, as cells with different
phenotypes may be the ones surviving each time this cycle
occurs. The cell clones that have very distinct expression
profiles, and maintain their expression profiles during
subsequent thaws and reculture from low-temperature
storage, provide further evidence of this phenomenon. In
another sense, a recent study showed that when rheuma-
toid arthritis synovial fibroblast (RASF) cells were in cul-
ture, as the culture passages increased from 2 to 8, up to
10% of the genes within this cell line are differentially
expressed [58]. In contrast to our observations, however,
after long-term storage, gene expression within the RASF
after passage 2 was comparable to gene expression prior
to freezing [58]. This is the first study to show that long-
term storage of stably transfected cells of the HPC, mono-
cytic, and T-cell lineages can result in alterations in gene
expression patterns.
TNF-α treatment of each of the stably transfected cell
line populations was performed to determine how each
SNP of interest might impact the way the LTR drives
GFP expression when observed from cell populations re-
covered from long-term low- temperature storage. Stably
transfected U-937 cells containing the 3 T and 3T5T
LTRs exhibited 2.34- and 2.55-fold increases in MFI, re-
spectively, with TNF-α stimulation. The difference in
LTR-driven gene transcription with LTRs containing the
WT, 3 T, 5 T, and 3T5T SNPs between stably transfected
TF-1 and U-937 cells could be attributed to the differ-
ence in cell types and the availability of specific tran-
scription factors and inherent viral gene activities within
those cells. Within the stably transfected TF-1 cells treated
with TNF-α, the 5 T LTR resulted in a higher level of
change in LTR-driven GFP expression than the WT LTR
(Figure 3). This observation indicates that although this
genotype (which occurs frequently in the DREXELMED
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evading immune activation within the host under basal
conditions, under stimulatory conditions it might be acti-
vated to produce a higher level of gene expression and
virus production. Additionally, TNF-α stimulation of the
stably transfected TF-1 and U-937 cells (Figure 3) sug-
gested that a 3T5T LTR-containing proviral DNA could
remain quiescent under certain metabolic conditions or in
a basal viral gene expression mode. Only minimal intracel-
lular stimulatory conditions would be required to drive
low levels of viral gene expression and virus production
within these cell populations, allowing evasion of HAART
elimination of the infecting cell. The viral genome con-
taining the 3T5T LTR could promote the evasion of ef-
fective HAART elimination, potentially contributing to
the development of a niched viral reservoir for virus with
specific genetic signatures that favor the quiescent or low-
level gene expression mode. Subsequently, when an in-
fected patient has a proinflammatory response to either
the HIV-1 infection or an opportunistic infection, the
3T5T double-variant LTR-containing viral genotype could
again result in an activation of the viral genome from a la-
tent viral reservoir. This conclusion has been based on the
increase in NF-κB binding to the 3T5T double variant and
enhanced operation of these low-affinity C/EBP and Sp
binding sites in the presence of elevated levels of the
corresponding activation factors and a repopulation of cir-
culating virus within the patient’s peripheral blood and
lymphoid tissues and within specialized reservoirs. These
changes would thereby make HAART less effective in re-
moving and reducing virus from within the immune and
nervous systems as well as other end organs.
The cell clones from each stably transfected cell line
containing the WT, 3 T, 5 T, or 3T5T LTRs were devel-
oped to facilitate studies to explain the observable differ-
ences between each of the LTRs within each cell line.
The low-GFP-expressing 3T5T LTR-containing TF-1 cell
clone exhibited a larger difference in MFI between un-
stimulated and stimulated conditions compared with the
intermediate-GFP-expressing cell clone. This observation
may suggest that virus containing the 3T5T LTR genotype
with a low enough expression profile in the body to facili-
tate evasion of HAART and the immune response, could,
under stimulated conditions, produce a large amount of
virus, reseeding infection into the body, possibly with viral
strains that may be more resistant to treatment. These ob-
servations suggest that across LTRs containing each of the
SNPs of interest (3 T, 5 T, and 3T5T), there is a differen-
tial expression within individual GFP-expressing clones.
These results also show that within an LTR, in this case
the 3T5T-containing LAI LTR, stimulation by cytokines
naturally occurring during inflammation and infection can
lead to differential regulation of the LTR between different
cell lines. In addition, non-GFP-expressing cell clones,regardless of the LTR or cell type, could not be induced
into expression with TNF-α stimulation, whereas the
intermediate- and high-GFP-expressing cell clones con-
taining each SNP of interest could be induced. This
important result shows that differences in regulation of
LTR-driven expression may also be attributable to the lo-
cation of integration within the human genome, proviral
DNA copy number, or possibly differences in epigenetic
controls operative on the LTRs.
Conclusions
The experimental approach used in this study has pro-
vided a means for understanding SNP-specific LTR func-
tion within models of HIV-1-susceptible cells. However,
this approach has not been without its limitations. In the
model system used in this study, the function of the LTR
is only observed within the context of an integrated plas-
mid. In addition, only the LAI backbone is used, which
has been derived from an X4-tropic virus. The LAI back-
bone was used because (1) it has been commonly used in
other scientific studies, (2) across the 12 binding sites
within the LTR, it shares sequence similarity with the
conB sequence except that it contains a 6G change within
C/EBP site I, and (3) full-length HIV-1 LAI virus has the
ability to infect all three cell line models used in this study.
It would be interesting to determine the effects of the
other LTR backbones, such as YU-2, an R5 virus, and
89.6, which has been defined to be an X4/R5 virus, on
SNP-specific LTR driven gene expression within stably
transfected TF-1, U-937, and Jurkat cells. It would also be
important to determine whether the effects of these SNPs
on LTR-driven gene expression observed within the stably
transfected cells used in this study would remain if full-
length pseudotype virus developed from molecular clones
using the different HIV-1 backbones were used to infect
the HPCs, monocytes, and T cells.
We have shown that the 3 T SNP within C/EBP binding
site I and the 5 T SNP within Sp binding site III, both pre-
viously reported to correlate with differential binding of
the C/EBP and Sp transcription factors for their cognate
binding sites [23,25-27,43,44], cause differential regulation
of gene expression by the LTR. We also showed that the
combination of the two SNPs leads to low levels of LTR-
driven GFP expression. The low levels of the double vari-
ant LTR-driven GFP expression could translate to a virus
with a selective advantage, enhancing viral survival and
facilitate the evasion of HAART therapy as well as the
host immune response to viral infection. Under activating
physiological conditions in the host, selected viral quasis-
pecies of low fitness under basal conditions with appropri-
ate cis-acting LTR elements could retain the ability to
respond to activating stimuli and replicate at higher
levels. They could thereby reseed infection into numer-
ous compartments, once again expanding the quantity
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iphery which could potentially cross the BBB reseeding
virus in the CNS.
Methods
Cell culture
The TF-1 CD34+ erythromyeloid leukemia cell line (ATCC,
Manassas, VA) was grown in RPMI 1640 medium with
L-glutamine (Cellgro, Herndon, VA) supplemented with
10% heat-inactivated fetal bovine serum (FBS; GemCell,
West Sacramento, CA), antibiotics (penicillin and strepto-
mycin, at a concentration of 0.04 mg/mL each; Cellgro),
glucose (4.5 g/mL; Cellgro), sodium pyruvate (1 mM;
Cellgro) and HEPES (10 mM; Cellgro), and recombinant
human granulocyte-macrophage colony stimulating factor
(2 ng/mL; eBioscience, San Diego, CA). The cells were
maintained at a density between 1–5 × 105 cells/mL.
The U-937 human promonocytic cell line (ATCC,
CRL-1593.2) was grown in RPMI 1640 medium with L-
glutamine supplemented with 10% heat-inactivated FBS,
antibiotics (penicillin and streptomycin, at a concentra-
tion of 0.04 mg/mL each), glucose (4.5 g/mL), sodium
pyruvate (1 mM), and HEPES (10 mM). The cells were
maintained at a density between 1–5 × 105 cells/mL.
The human T-cell line Jurkat (ATCC, TIB-152) was
grown in RPMI 1640 medium with L-glutamine supple-
mented with 10% heat-inactivated FBS, sodium bicar-
bonate (0.05%), and antibiotics (penicillin, streptomycin,
and kanamycin at 0.04 mg/mL each). The cells were main-
tained at a density between 1 × 105 and 1 × 106 cells/mL
as recommended by ATCC. All cells were maintained at
37°C in 5% CO2 at 90% relative humidity.
Plasmid construction and site-directed mutagenesis
The HIV-1 LAI LTR sequence was amplified by PCR
from previously published LAI-LTR-Luc reporter con-
structs [59,60]. The following primers were used for the
amplification of LAI LTR: 5′-GGC-CGG-ATT-AAT-TGG-
AAG -GGC-TAA-TTC-ACT-CC-3′ and 5′-GAC-CGG-
TTG-CTA-GAG-ATT-TTC-CAC-AC T-G-3′ (Integrated
DNA Technologies). Following amplification, the HIV-1
LAI LTR was cloned into the pEGFP-N1 vector (Clontech,
Mountain View, CA), which contains the eGFP gene. The
PCR product and the pEGFP-N1 vector were digested
with the VspI (AseI) and the BshTI (AgeI) restriction en-
zymes and the digested PCR product was ligated into
the digested pEGFP-N1 vector, generating the LAI LTR-
GFP reporter construct.
Site-directed mutagenesis (SDM) was performed using
the QuickChange mutagenesis procedure (Stratagene, La
Jolla, CA) on the HIV-1 LAI LTR-GFP reporter construct
to incorporate a C-to-T mutation at position 5 of the Sp
site III (5 T). The following primers were used: CTT TCC
AGG GAG GTG TGG CCT GGG CG and CGC CCAGGC CAC ACC TCC CTG GAA AG. The mutagenized
nucleotide is underlined. This process generated the LAI
LTR-5 T-GFP reporter construct. SDM was also per-
formed on the HIV-1 LAI LTR-GFP reporter construct to
incorporate a C-to-T mutation at position 3 of the C/EBP
site I (3 T). The following primers were used: GCT GAC
ATC GAG TTT GCT ACA AGG G and CCC TTG TAG
CAA ACT CGA TGT CAG C. The mutagenized nucleo-
tide is underlined. This process generated the LAI LTR-
3 T-GFP, which was used for an additional round of SDM
to incorporate a C-to-T mutation at position 5 of the Sp
site III (5 T) as indicated previously. This process gener-
ated the LAI LTR-3T5T-GFP reporter constructs. For
both the parental and mutated HIV-1 LTR constructs au-
thenticity was confirmed by DNA sequencing (Genewiz,
South Plainfield, NJ) and sequence analyses using Laser-
gene software (DNASTAR, Inc., Madison, WI).
Stable transfection of TF-1, U-937, and Jurkat cells and
stably transfected cell clone development
TF-1, U-937, and Jurkat cells (ATCC) were transfected
with the constructs using the AMAXA Nucleofector
System and AMAXA procedure V, as described by the
manufacturer (Lonza, Basel, Switzerland). Transfected
cells were passaged under G418 (800 ng/mL; Mediatech,
Manassas, VA) selection beginning 24 hours after trans-
fection and passaged under G418 selection for at least
2 months to develop stably transfected populations. The
TF-1 and U-937 cell populations were each serially diluted
to a final concentration of 1 cell/mL media and plated into
96-well plates, where they were marked and tracked for
growth. Once clonal cells became a confluent clonal
population within the well, they were moved to a larger
well with more media until they could be transferred to
flasks and propagated normally. Basal levels of LTR-driven
GFP expression within each cell population and clonal
population were measured using flow cytometry.
Assessment of GFP expression utilizing flow cytometry
TF-1, U-937, and Jurkat cells were washed with flow
cytometry buffer [Hanks balanced saline solution (Med-
iatech), FBS (3%), and NaN3 (0.02%)] and aliquots of
1 × 106 cells were fixed with paraformaldehyde (1%).
Flow cytometry analysis was performed utilizing a Calibur
Flow Cytometer (BD Biosciences, San Diego, CA) and an-
alyzed the results using Flowjo version 8.8.7 software
(Tree Star, Ashland, OR).
Oligonucleotide synthesis and radiolabeling
Complementary single-stranded oligonucleotides corre-
sponding to the LAI LTR with and without the 3 T SNP
in C/EBP site I and/or the 5 T SNP in Sp site III were
synthesized (Integrated DNA Technologies) and annealed
by brief heating at 100°C followed by slow cooling to room
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double-stranded oligonucleotides were end-labeled using
32P-ATP and T4 polynucleotide kinase as described (Pro-
mega, Madison, WI). The sequences of the probes used in
this study are as follows: LAI LTR WT: TCG AGC TTG
CTA CAA GGG ACT TTC CGC TGG GGA CTT TCC
AGG GAG GCG TGG CC; LAI LTR 3 T: TCG AGT
TTG CTA CAA GGG ACT TTC CGC TGG GGA CTT
TCC AGG GAG GCG TGG CC; LAI LTR 5 T: TCG
AGC TTG CTA CAA GGG ACT TTC CGC TGG GGA
CTT TCC AGG GAG GTG TGG CC; LAI LTR 3T5T:
TCG AGT TTG CTA CAA GGG ACT TTC CGC TGG
GGA CTT TCC AGG GAG GTG TGG CC. The SNPs
are indicated as underlined nucleotides.
Electromobility shift analysis
Electrophoretic mobility shift assay binding reactions were
performed as previously described [37]. The radiolabeled
LAI LTR probes were incubated with activated [TNF-α
(20 ng/mL) for 24 hours] or normal nuclear extract from
TF-1 cells for 30 minutes at 4°C in the presence of with
poly[dI-dC)] (1 μg), bovine serum albumin (BSA), and 1×
binding buffer. Reactions (20 μL, final volume) were sup-
plemented with BSA (15 μg). The following antibodies
(Santa Cruz Biotechnology, Santa Cruz, CA) were used to
determine complex formation: NF-κB p50 (H-119X), NF-
κB p65 (C-20X). DNA-protein complexes were resolved at
4°C by electrophoresis for 3 hours at 200 V in a 4.5% non-
denaturing polyacrylamide gel, which was then dried at
80°C for 2.5 hours and used for autoradiography.
Nuclear protein extraction from TF-1, U-937, and Jurkat cells
Nuclear protein extraction was performed as previously
described [61]. Briefly, 3 × 107 cells were harvested for
each nuclear extraction and washed once with 1×
phosphate-buffered saline. The cells were incubated for
15 minutes with lysis buffer on ice and then 2 μL 10%
NP-40 detergent was added and cells were inverted sev-
eral times. Cells were centrifuged at 1100 RPM for 5 mi-
nutes and then resuspended, through inverting, in lysis
buffer and then centrifuged again. The nuclei pellets
were then resuspended in nuclear extract buffer and
then incubated for at 4°C for 30 minutes on a vortexer
set to a speed of 3. The nuclear lysate was centrifuged at
14,000 RPM for 10 minutes at 4°C, after which time the
supernatant was removed and quantitated with respect
to protein concentration as previously described [62].
Nuclear extracts were then stored at −80°C.
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